 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12 |
- volagidemab (REMD-477) / Amgen, REMD Bio
Enrollment open: Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Apr 20, 2016
P1, N=20, Recruiting, Sponsor: REMD Biotherapeutics, Inc.
Not yet recruiting --> Recruiting
- | volagidemab (REMD-477) / Amgen, REMD Bio
New P1 trial: Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Mar 22, 2016
P1, N=20, Not yet recruiting, Sponsor: REMD Biotherapeutics, Inc.
- |||| volagidemab (REMD-477) / Amgen, REMD Bio
Enrollment open: Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Sep 9, 2015
P1/2, N=72, Recruiting, Sponsor: REMD Biotherapeutics, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | volagidemab (REMD-477) / Amgen, REMD Bio
New P1/2 trial: Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - May 27, 2015
P1/2, N=72, Not yet recruiting, Sponsor: REMD Biotherapeutics, Inc.